Medtech
Total restructuring charges related to the plan were $6.8m as of the end of December. Photo: Stock image/Getty
A multinational medical device manufacturing giant is to shift much of its research and product development operations from Israel to Ireland.
In its annual results, Texas-headquartered Integer Holdings shared details of its plan to consolidate existing research and product development operations, primarily into a new Irish facility. The move by the New York Stock Exchange-listed company started in 2023 and is part of a plan to “more efficiently meet customer needs”.